v3.26.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
OPERATING REVENUE:        
TOTAL OPERATING REVENUE $ 386,381 $ 355,788 $ 772,771 $ 729,013
OPERATING EXPENSE:        
Medical expense 300,377 351,350 636,401 723,393
Premium deficiency reserve (8,659) (5,967) (13,374) (12,929)
Corporate, general and administrative expense 32,393 23,446 58,163 48,626
Depreciation and amortization 21,044 21,083 42,118 42,135
TOTAL OPERATING EXPENSE 345,155 389,912 723,308 801,225
OPERATING INCOME (LOSS) 41,226 (34,124) 49,463 (72,212)
OTHER INCOME (EXPENSE):        
Interest expense, net (7,862) (10,145) (24,628) (18,870)
Mark-to-market of stock warrants and purchased put option (16,366) 2,002 (16,036) 5,324
Other (82) 583 160 901
TOTAL OTHER EXPENSE (24,310) (7,560) (40,504) (12,645)
INCOME (LOSS) BEFORE INCOME TAXES 16,916 (41,684) 8,959 (84,857)
INCOME TAX BENEFIT (PROVISION) (1,265) (1,981) 9,732 (3,054)
NET INCOME (LOSS) 15,651 (43,665) 18,691 (87,911)
LESS: NET INCOME (LOSS) ATTRIBUTABLE TO NON-CONTROLLING INTERESTS 8,207 (23,303) 10,024 (47,069)
NET INCOME (LOSS) ATTRIBUTABLE TO CONTROLLING INTEREST 7,444 (20,362) 8,667 (40,842)
LESS: CUMULATIVE PREFERRED STOCK DIVIDENDS 9,570 0 9,570 0
Net loss attributable to Class A common stockholders–basic $ (2,126) $ (20,362) $ (903) $ (40,842)
NET LOSS PER SHARE (Note 9):        
Basic (in dollars per share) $ (0.63) $ (6.23) $ (0.27) $ (12.52)
Diluted (in dollars per share) $ (0.63) $ (6.23) $ (0.27) $ (12.52)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (Note 9):        
Basic (in shares) 3,362 3,267 3,325 3,263
Diluted (in shares) 3,362 3,267 3,325 3,263
Capitated revenue        
OPERATING REVENUE:        
TOTAL OPERATING REVENUE $ 366,398 $ 351,724 $ 745,897 $ 721,241
Other patient service revenue        
OPERATING REVENUE:        
TOTAL OPERATING REVENUE $ 19,983 $ 4,064 $ 26,874 $ 7,772